Abstract
BACKGROUND: Oligodendroglioma is a specific type of brain glioma, and relatively little research has been conducted on it. The expression and prognosis of serine protease peptidase inhibitor, branch H, member 1 (SERPINH1) in some malignant tumors have been studied, but the prognosis value and potential mechanism of this gene in oligodendroglioma have not been reported yet, and further research is needed. This study aims to reveal the expression characteristics and biological functions of SERPINH1 in oligodendroglioma cells, laying the foundation for targeted drug development. METHODS: Retrospective RNA sequencing (RNA-seq) data analysis was conducted in a cohort of 171 patients with oligodendroglioma in the Chinese Glioma Genome Atlas (CGGA) database and 149 patients in The Cancer Genome Atlas (TCGA) database. In addition, we used Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), and Kaplan-Meier analyses, univariate and multivariate Cox regression analyses, correlation analysis, as well as Kolmogorov-Smirnov test and Unpaired t-test. RESULTS: SERPINH1 is highly enriched in short-lived patients compared to long-lived oligodendroglioma patients. SERPINH1 is relatively highly expressed in more malignant oligodendrogliomas. Functional enrichment shows that SERPINH1 is closely related to the tumor invasion function of oligodendroglioma. Further research has confirmed that SERPINH1 promotes the invasive function of tumor cells by regulating the secretion of extracellular matrix. Prognostic analysis shows that SERPINH1 is an independent poor prognostic factor for oligodendroglioma. CONCLUSIONS: We found that SERPINH1 can serve as an independent prognostic biomarker for oligodendroglioma. It may be a potential new target for the treatment of oligodendroglioma.